ARCHIMED

ARCHIMED is a global investment firm focused on healthcare industries. It invests through buyout funds in small-cap and mid-cap growth transactions with companies in seven targeted healthcare sectors, and supports them through internationalization, innovation and M&A. Portfolio companies named on its website include Direct Healthcare Group, Arkstone, Stragen, Instem, ExcellGene, Suanfarma and Genetica.

Its counterparties are healthcare companies it acquires and the investors in its funds. The website states that it invests between €10 million and €1 billion per transaction and reports that the MED IV fund closed at a €1.5 billion hard cap in September 2026.

The firm was founded by healthcare professionals and has headquarters in New York and Lyon, with offices in North America, Europe and Asia. The website states it has more than 160 team members. Its open roles are mostly in Lyon and cover investment, business development, risk, HR and internship positions, with additional roles at portfolio companies in Germany and Switzerland.

Product: Growth buyout private equity funds (MED series) that invest in healthcare companies, with operational and strategic support to portfolio companies.